메뉴 건너뛰기




Volumn 26, Issue 1, 2010, Pages 43-55

Genetic interventions in mammalian cells; Applications and uses in high-throughput screening and drug discovery

Author keywords

Cellular assays; Drug discovery; GPCR; Target manipulation

Indexed keywords

CELL ASSAY; CELL LINE; DNA MODIFICATION; DRUG DELIVERY SYSTEM; DRUG RESEARCH; DRUG TARGETING; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 76749161255     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10565-009-9140-z     Document Type: Review
Times cited : (7)

References (18)
  • 1
    • 33645675960 scopus 로고    scopus 로고
    • Estimating the cost of new drug development: Is it really 802 million dollars?
    • 10.1377/hlthaff.25.2.420
    • CP Adams VV Brantner 2006 Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 25 2 420 428 10.1377/hlthaff.25.2.420
    • (2006) Health Aff (Millwood) , vol.25 , Issue.2 , pp. 420-428
    • Adams, C.P.1    Brantner, V.V.2
  • 2
    • 0028874181 scopus 로고
    • GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors
    • 10.1016/0014-2999(94)00655-Q 1:CAS:528:DyaK2MXjt1Smsrw%3D 7713168
    • IJ Beresford, et al. 1995 GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors Eur J Pharmacol 272 2-3 241 248 10.1016/0014-2999(94) 00655-Q 1:CAS:528:DyaK2MXjt1Smsrw%3D 7713168
    • (1995) Eur J Pharmacol , vol.272 , Issue.23 , pp. 241-248
    • Beresford, I.J.1
  • 3
    • 23044504046 scopus 로고    scopus 로고
    • How many genomics targets can a portfolio afford?
    • DOI 10.1016/S1359-6446(05)03498-7, PII S1359644605034987
    • UAK Betz 2005 How many genomics targets can a portfolio afford? Drug Discov Today 10 15 1057 1063 10.1016/S1359-6446(05)03498-7 16055022 (Pubitemid 41074144)
    • (2005) Drug Discovery Today , vol.10 , Issue.15 , pp. 1057-1063
    • Betz, U.A.K.1
  • 4
    • 66049129455 scopus 로고    scopus 로고
    • Assessment of methods and analysis of outcomes for comprehensive optimization of nucleofection
    • 10.1186/1479-0556-7-6 19432988
    • C Bradburne K Robertson D Thach 2009 Assessment of methods and analysis of outcomes for comprehensive optimization of nucleofection Genet Vaccines Ther 7 6 10.1186/1479-0556-7-6 19432988
    • (2009) Genet Vaccines Ther , vol.7 , pp. 6
    • Bradburne, C.1    Robertson, K.2    Thach, D.3
  • 5
    • 35148830392 scopus 로고    scopus 로고
    • Evolution of cell-based reagent provision
    • DOI 10.1016/j.drudis.2007.08.014, PII S135964460700356X
    • D Cawkill SS Eaglestone 2007 Evolution of cell-based reagent provision Drug Discov Today 12 19-20 820 825 10.1016/j.drudis.2007.08.014 1:CAS:528:DC%2BD2sXhtFKitrfL 17933682 (Pubitemid 47539971)
    • (2007) Drug Discovery Today , vol.12 , Issue.19-20 , pp. 820-825
    • Cawkill, D.1    Eaglestone, S.S.2
  • 6
    • 0024236673 scopus 로고
    • The mechanism of conservative site-specific recombination
    • 10.1146/annurev.ge.22.120188.000453 1:CAS:528:DyaL1MXhs1Krt7g%3D 3071260
    • NL Craig 1988 The mechanism of conservative site-specific recombination Ann Rev Genet 22 77 105 10.1146/annurev.ge.22.120188.000453 1:CAS:528: DyaL1MXhs1Krt7g%3D 3071260
    • (1988) Ann Rev Genet , vol.22 , pp. 77-105
    • Craig, N.L.1
  • 7
    • 41949098086 scopus 로고    scopus 로고
    • Nucleofection is a highly effective gene transfer technique for human melanoma cell lines
    • 10.1111/j.1600-0625.2007.00687.x 1:CAS:528:DC%2BD1cXmslKlt7s%3D 18312380
    • CY Han, et al. 2008 Nucleofection is a highly effective gene transfer technique for human melanoma cell lines Exp Dermatol 17 5 405 411 10.1111/j.1600-0625.2007.00687.x 1:CAS:528:DC%2BD1cXmslKlt7s%3D 18312380
    • (2008) Exp Dermatol , vol.17 , Issue.5 , pp. 405-411
    • Han, C.Y.1
  • 8
    • 0035489204 scopus 로고    scopus 로고
    • Reporter-gene systems for the study of G-protein-coupled receptors
    • DOI 10.1016/S1471-4892(01)00091-1
    • SJ Hill, et al. 2001 Reporter-gene systems for the study of G-protein-coupled-receptors Curr Opin Pharmacol 1 526 532 10.1016/S1471-4892(01) 00091-1 1:CAS:528:DC%2BD3MXnsFOisr8%3D 11764780 (Pubitemid 33593844)
    • (2001) Current Opinion in Pharmacology , vol.1 , Issue.5 , pp. 526-532
    • Hill, S.J.1    Baker, J.G.2    Rees, S.3
  • 9
    • 7244245762 scopus 로고    scopus 로고
    • Finishing the euchromatic sequence of the human genome
    • DOI 10.1038/nature03001
    • Human Genome Sequencing Consortium 2004 Finishing the euchromatic sequence of the human genome Nature 431 7011 931 945 10.1038/nature03001 (Pubitemid 39434409)
    • (2004) Nature , vol.431 , Issue.7011 , pp. 931-945
    • Collins, F.S.1    Lander, E.S.2    Rogers, J.3    Waterson, R.H.4
  • 10
    • 27144434813 scopus 로고    scopus 로고
    • Techniques: Promiscuous Gα proteins in basic research and drug discovery
    • DOI 10.1016/j.tips.2005.09.007, PII S0165614705002397
    • E Kostenis M Waelbroeck G Milligan 2005 Techniques: promiscuous Galpha proteins in basic research and drug discovery Trends Pharmacol Sci 26 11 595 602 10.1016/j.tips.2005.09.007 1:CAS:528:DC%2BD2MXhtFKhsrrM 16183138 (Pubitemid 41505228)
    • (2005) Trends in Pharmacological Sciences , vol.26 , Issue.11 , pp. 595-602
    • Kostenis, E.1    Waelbroeck, M.2    Milligan, G.3
  • 12
    • 0027397351 scopus 로고
    • Tachykinin receptors and tachykinin receptor antagonists
    • 10.1111/j.1474-8673.1993.tb00396.x 1:CAS:528:DyaK3sXhtl2qu74%3D 8382703
    • CA Maggi R Patacchini P Rovero A Giachetti 1993 Tachykinin receptors and tachykinin receptor antagonists J Auton Pharmacol 13 1 23 93 10.1111/j.1474-8673.1993.tb00396.x 1:CAS:528:DyaK3sXhtl2qu74%3D 8382703
    • (1993) J Auton Pharmacol , vol.13 , Issue.1 , pp. 23-93
    • Maggi, C.A.1    Patacchini, R.2    Rovero, P.3    Giachetti, A.4
  • 13
    • 79951779464 scopus 로고    scopus 로고
    • The cost of developing a new drug
    • US Department of State (eds) US Department of State Washington, DC
    • Masia N. The cost of developing a new drug. In: US Department of State, editor. Focus on: intellectual property rights. Washington, DC: US Department of State; 2006. p. 82-3.
    • (2006) Focus On: Intellectual Property Rights , pp. 82-83
    • Masia, N.1
  • 14
    • 34447580978 scopus 로고    scopus 로고
    • The A, B, Cs of G-protein-coupled receptor pharmacology in assay development for HTS
    • DOI 10.1517/17460441.2.5.603
    • DJ McLoughlin F Bertelli C Williams 2007 The A, B, Cs of G-protein-coupled receptor pharmacology in assay development for HTS Expert Opin Drug Discov 2 5 603 619 10.1517/17460441.2.5.603 1:CAS:528:DC%2BD2sXotFyntbc%3D (Pubitemid 47071655)
    • (2007) Expert Opinion on Drug Discovery , vol.2 , Issue.5 , pp. 603-619
    • McLoughlin, D.J.1    Bertelli, F.2    Williams, C.3
  • 15
    • 33751547539 scopus 로고    scopus 로고
    • How many drug targets are there?
    • DOI 10.1038/nrd2199, PII NRD2199
    • JP Overington B Al-Lazikani AL Hopkins 2006 How many drug targets are there? Nat Rev Drug Discov 5 993 996 10.1038/nrd2199 1:CAS:528: DC%2BD28Xht1Kju7jM 17139284 (Pubitemid 44835126)
    • (2006) Nature Reviews Drug Discovery , vol.5 , Issue.12 , pp. 993-996
    • Overington, J.P.1    Al-Lazikani, B.2    Hopkins, A.L.3
  • 16
    • 0028148244 scopus 로고
    • Site-specific recombination: Developments and applications
    • DOI 10.1016/0958-1669(94)90068-X
    • B Sauer 1994 Site-specific recombination: developments and applications Curr Opin Biotechnol 5 521 527 10.1016/0958-1669(94)90068-X 1:CAS:528: DyaK2MXhvV2gu70%3D 7765467 (Pubitemid 24321421)
    • (1994) Current Opinion in Biotechnology , vol.5 , Issue.5 , pp. 521-527
    • Sauer, B.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.